Action Needed : Spiraling Drug Prices Empty Russian Pockets
In large measure, this is due to the relatively low level of public health spending in the country (about 3.6 percent of gross domestic product (GDP) in 2008) that underlines the significant gap between the constitutional commitment to a range of medical care services and the actual funding to pay for them. While drugs are supposed to be provided to hospital patients free of charge, an estimated 80 percent of inpatients still have to pay part of the costs of their medicines and most outpatients must purchase them from pharmacies. The outpatient drug program under mandatory health insurance covers only around 16 million people (11 percent of the total population in the country), with more than half of them opting to receive cash rather than in-kind benefits under the 2005 'monetization' of prescription drug benefits. Those who continue with the in-kind benefits appear to be the ones greatest in need of drugs. The situation is further aggravated by the country's ineffective enforcement of controls on wholesale and retail mark-ups for medicines. Household expenditure on drugs accounted for about 30 percent of total health expenditure in Russia, as compared to 12 percent in Organization for Economic Co-operation and Development (OECD) countries in 2008.
Saved in:
| id |
dig-okr-1098610211 |
|---|---|
| record_format |
koha |
| spelling |
dig-okr-10986102112024-08-08T16:11:23Z Action Needed : Spiraling Drug Prices Empty Russian Pockets Marquez, Patricio Bonch-Osmolovskiy, Mikhail ASPIRIN BRAND BRAND NAME BRAND NAME DRUGS CARDIOVASCULAR DISEASES CHRONIC DISEASE CHRONIC DISEASES CLINICAL GUIDELINES COMPETITIVENESS CONSUMER PRICE CONSUMER PRICE INDEX DEMOGRAPHIC CHANGE DEPRECIATION DIABETES DRUG LIST DRUG POLICIES DRUG PRICES DRUG RESISTANCE DRUGS ESSENTIAL DRUGS ESSENTIAL MEDICINES EXPENDITURE EXPENDITURES FAMILIES GENERIC DRUGS GENERIC EQUIVALENTS HEALTH CARE HEALTH ECONOMICS HEALTH INFORMATION SYSTEMS HEALTH INSURANCE HEALTH OUTCOMES HEALTH PROBLEMS HEALTH REFORM HEALTH RESEARCH HEALTH SERVICES HEALTH SYSTEM HOSPITAL HOSPITAL CARE HOSPITAL PATIENTS HOSPITALIZATION HUMAN DEVELOPMENT HYPERTENSION ILL HEALTH ILLNESSES INFORMED DECISIONS INJURIES INSULIN INTERNATIONAL MARKET MARKETING MEDICAL CARE MEDICAL EDUCATION MEDICINES MENTAL DISORDERS MORTALITY PATIENT PATIENTS PHARMACEUTICAL PHARMACEUTICAL INDUSTRY PHARMACEUTICALS PHARMACIES PHYSICIANS POLICY MAKERS POPULATION GROUPS PRICE CONTROLS PRICE INCREASE PRICE INCREASES PRICE INFLATION PROCUREMENT PUBLIC HEALTH RATIONAL DRUG USE RETAIL RETAIL PRICE RETAIL PRICES SALES SOCIAL SECTORS SOCIAL WELFARE SUPPLIERS TENDERING THERAPIES TUBERCULOSIS UNEMPLOYMENT WHOLESALE PRICES In large measure, this is due to the relatively low level of public health spending in the country (about 3.6 percent of gross domestic product (GDP) in 2008) that underlines the significant gap between the constitutional commitment to a range of medical care services and the actual funding to pay for them. While drugs are supposed to be provided to hospital patients free of charge, an estimated 80 percent of inpatients still have to pay part of the costs of their medicines and most outpatients must purchase them from pharmacies. The outpatient drug program under mandatory health insurance covers only around 16 million people (11 percent of the total population in the country), with more than half of them opting to receive cash rather than in-kind benefits under the 2005 'monetization' of prescription drug benefits. Those who continue with the in-kind benefits appear to be the ones greatest in need of drugs. The situation is further aggravated by the country's ineffective enforcement of controls on wholesale and retail mark-ups for medicines. Household expenditure on drugs accounted for about 30 percent of total health expenditure in Russia, as compared to 12 percent in Organization for Economic Co-operation and Development (OECD) countries in 2008. 2012-08-13T10:44:33Z 2012-08-13T10:44:33Z 2010-02 http://documents.worldbank.org/curated/en/2010/02/11900772/action-needed-spiraling-drug-prices-empty-russian-pockets https://hdl.handle.net/10986/10211 English Europe and Central Asia Knowledge Brief; Volume No. 19 CC BY 3.0 IGO http://creativecommons.org/licenses/by/3.0/igo/ World Bank application/pdf text/plain World Bank, Washington, DC |
| institution |
Banco Mundial |
| collection |
DSpace |
| country |
Estados Unidos |
| countrycode |
US |
| component |
Bibliográfico |
| access |
En linea |
| databasecode |
dig-okr |
| tag |
biblioteca |
| region |
America del Norte |
| libraryname |
Biblioteca del Banco Mundial |
| language |
English |
| topic |
ASPIRIN BRAND BRAND NAME BRAND NAME DRUGS CARDIOVASCULAR DISEASES CHRONIC DISEASE CHRONIC DISEASES CLINICAL GUIDELINES COMPETITIVENESS CONSUMER PRICE CONSUMER PRICE INDEX DEMOGRAPHIC CHANGE DEPRECIATION DIABETES DRUG LIST DRUG POLICIES DRUG PRICES DRUG RESISTANCE DRUGS ESSENTIAL DRUGS ESSENTIAL MEDICINES EXPENDITURE EXPENDITURES FAMILIES GENERIC DRUGS GENERIC EQUIVALENTS HEALTH CARE HEALTH ECONOMICS HEALTH INFORMATION SYSTEMS HEALTH INSURANCE HEALTH OUTCOMES HEALTH PROBLEMS HEALTH REFORM HEALTH RESEARCH HEALTH SERVICES HEALTH SYSTEM HOSPITAL HOSPITAL CARE HOSPITAL PATIENTS HOSPITALIZATION HUMAN DEVELOPMENT HYPERTENSION ILL HEALTH ILLNESSES INFORMED DECISIONS INJURIES INSULIN INTERNATIONAL MARKET MARKETING MEDICAL CARE MEDICAL EDUCATION MEDICINES MENTAL DISORDERS MORTALITY PATIENT PATIENTS PHARMACEUTICAL PHARMACEUTICAL INDUSTRY PHARMACEUTICALS PHARMACIES PHYSICIANS POLICY MAKERS POPULATION GROUPS PRICE CONTROLS PRICE INCREASE PRICE INCREASES PRICE INFLATION PROCUREMENT PUBLIC HEALTH RATIONAL DRUG USE RETAIL RETAIL PRICE RETAIL PRICES SALES SOCIAL SECTORS SOCIAL WELFARE SUPPLIERS TENDERING THERAPIES TUBERCULOSIS UNEMPLOYMENT WHOLESALE PRICES ASPIRIN BRAND BRAND NAME BRAND NAME DRUGS CARDIOVASCULAR DISEASES CHRONIC DISEASE CHRONIC DISEASES CLINICAL GUIDELINES COMPETITIVENESS CONSUMER PRICE CONSUMER PRICE INDEX DEMOGRAPHIC CHANGE DEPRECIATION DIABETES DRUG LIST DRUG POLICIES DRUG PRICES DRUG RESISTANCE DRUGS ESSENTIAL DRUGS ESSENTIAL MEDICINES EXPENDITURE EXPENDITURES FAMILIES GENERIC DRUGS GENERIC EQUIVALENTS HEALTH CARE HEALTH ECONOMICS HEALTH INFORMATION SYSTEMS HEALTH INSURANCE HEALTH OUTCOMES HEALTH PROBLEMS HEALTH REFORM HEALTH RESEARCH HEALTH SERVICES HEALTH SYSTEM HOSPITAL HOSPITAL CARE HOSPITAL PATIENTS HOSPITALIZATION HUMAN DEVELOPMENT HYPERTENSION ILL HEALTH ILLNESSES INFORMED DECISIONS INJURIES INSULIN INTERNATIONAL MARKET MARKETING MEDICAL CARE MEDICAL EDUCATION MEDICINES MENTAL DISORDERS MORTALITY PATIENT PATIENTS PHARMACEUTICAL PHARMACEUTICAL INDUSTRY PHARMACEUTICALS PHARMACIES PHYSICIANS POLICY MAKERS POPULATION GROUPS PRICE CONTROLS PRICE INCREASE PRICE INCREASES PRICE INFLATION PROCUREMENT PUBLIC HEALTH RATIONAL DRUG USE RETAIL RETAIL PRICE RETAIL PRICES SALES SOCIAL SECTORS SOCIAL WELFARE SUPPLIERS TENDERING THERAPIES TUBERCULOSIS UNEMPLOYMENT WHOLESALE PRICES |
| spellingShingle |
ASPIRIN BRAND BRAND NAME BRAND NAME DRUGS CARDIOVASCULAR DISEASES CHRONIC DISEASE CHRONIC DISEASES CLINICAL GUIDELINES COMPETITIVENESS CONSUMER PRICE CONSUMER PRICE INDEX DEMOGRAPHIC CHANGE DEPRECIATION DIABETES DRUG LIST DRUG POLICIES DRUG PRICES DRUG RESISTANCE DRUGS ESSENTIAL DRUGS ESSENTIAL MEDICINES EXPENDITURE EXPENDITURES FAMILIES GENERIC DRUGS GENERIC EQUIVALENTS HEALTH CARE HEALTH ECONOMICS HEALTH INFORMATION SYSTEMS HEALTH INSURANCE HEALTH OUTCOMES HEALTH PROBLEMS HEALTH REFORM HEALTH RESEARCH HEALTH SERVICES HEALTH SYSTEM HOSPITAL HOSPITAL CARE HOSPITAL PATIENTS HOSPITALIZATION HUMAN DEVELOPMENT HYPERTENSION ILL HEALTH ILLNESSES INFORMED DECISIONS INJURIES INSULIN INTERNATIONAL MARKET MARKETING MEDICAL CARE MEDICAL EDUCATION MEDICINES MENTAL DISORDERS MORTALITY PATIENT PATIENTS PHARMACEUTICAL PHARMACEUTICAL INDUSTRY PHARMACEUTICALS PHARMACIES PHYSICIANS POLICY MAKERS POPULATION GROUPS PRICE CONTROLS PRICE INCREASE PRICE INCREASES PRICE INFLATION PROCUREMENT PUBLIC HEALTH RATIONAL DRUG USE RETAIL RETAIL PRICE RETAIL PRICES SALES SOCIAL SECTORS SOCIAL WELFARE SUPPLIERS TENDERING THERAPIES TUBERCULOSIS UNEMPLOYMENT WHOLESALE PRICES ASPIRIN BRAND BRAND NAME BRAND NAME DRUGS CARDIOVASCULAR DISEASES CHRONIC DISEASE CHRONIC DISEASES CLINICAL GUIDELINES COMPETITIVENESS CONSUMER PRICE CONSUMER PRICE INDEX DEMOGRAPHIC CHANGE DEPRECIATION DIABETES DRUG LIST DRUG POLICIES DRUG PRICES DRUG RESISTANCE DRUGS ESSENTIAL DRUGS ESSENTIAL MEDICINES EXPENDITURE EXPENDITURES FAMILIES GENERIC DRUGS GENERIC EQUIVALENTS HEALTH CARE HEALTH ECONOMICS HEALTH INFORMATION SYSTEMS HEALTH INSURANCE HEALTH OUTCOMES HEALTH PROBLEMS HEALTH REFORM HEALTH RESEARCH HEALTH SERVICES HEALTH SYSTEM HOSPITAL HOSPITAL CARE HOSPITAL PATIENTS HOSPITALIZATION HUMAN DEVELOPMENT HYPERTENSION ILL HEALTH ILLNESSES INFORMED DECISIONS INJURIES INSULIN INTERNATIONAL MARKET MARKETING MEDICAL CARE MEDICAL EDUCATION MEDICINES MENTAL DISORDERS MORTALITY PATIENT PATIENTS PHARMACEUTICAL PHARMACEUTICAL INDUSTRY PHARMACEUTICALS PHARMACIES PHYSICIANS POLICY MAKERS POPULATION GROUPS PRICE CONTROLS PRICE INCREASE PRICE INCREASES PRICE INFLATION PROCUREMENT PUBLIC HEALTH RATIONAL DRUG USE RETAIL RETAIL PRICE RETAIL PRICES SALES SOCIAL SECTORS SOCIAL WELFARE SUPPLIERS TENDERING THERAPIES TUBERCULOSIS UNEMPLOYMENT WHOLESALE PRICES Marquez, Patricio Bonch-Osmolovskiy, Mikhail Action Needed : Spiraling Drug Prices Empty Russian Pockets |
| description |
In large measure, this is due to the
relatively low level of public health spending in the
country (about 3.6 percent of gross domestic product (GDP)
in 2008) that underlines the significant gap between the
constitutional commitment to a range of medical care
services and the actual funding to pay for them. While drugs
are supposed to be provided to hospital patients free of
charge, an estimated 80 percent of inpatients still have to
pay part of the costs of their medicines and most
outpatients must purchase them from pharmacies. The
outpatient drug program under mandatory health insurance
covers only around 16 million people (11 percent of the
total population in the country), with more than half of
them opting to receive cash rather than in-kind benefits
under the 2005 'monetization' of prescription drug
benefits. Those who continue with the in-kind benefits
appear to be the ones greatest in need of drugs. The
situation is further aggravated by the country's
ineffective enforcement of controls on wholesale and retail
mark-ups for medicines. Household expenditure on drugs
accounted for about 30 percent of total health expenditure
in Russia, as compared to 12 percent in Organization for
Economic Co-operation and Development (OECD) countries in 2008. |
| topic_facet |
ASPIRIN BRAND BRAND NAME BRAND NAME DRUGS CARDIOVASCULAR DISEASES CHRONIC DISEASE CHRONIC DISEASES CLINICAL GUIDELINES COMPETITIVENESS CONSUMER PRICE CONSUMER PRICE INDEX DEMOGRAPHIC CHANGE DEPRECIATION DIABETES DRUG LIST DRUG POLICIES DRUG PRICES DRUG RESISTANCE DRUGS ESSENTIAL DRUGS ESSENTIAL MEDICINES EXPENDITURE EXPENDITURES FAMILIES GENERIC DRUGS GENERIC EQUIVALENTS HEALTH CARE HEALTH ECONOMICS HEALTH INFORMATION SYSTEMS HEALTH INSURANCE HEALTH OUTCOMES HEALTH PROBLEMS HEALTH REFORM HEALTH RESEARCH HEALTH SERVICES HEALTH SYSTEM HOSPITAL HOSPITAL CARE HOSPITAL PATIENTS HOSPITALIZATION HUMAN DEVELOPMENT HYPERTENSION ILL HEALTH ILLNESSES INFORMED DECISIONS INJURIES INSULIN INTERNATIONAL MARKET MARKETING MEDICAL CARE MEDICAL EDUCATION MEDICINES MENTAL DISORDERS MORTALITY PATIENT PATIENTS PHARMACEUTICAL PHARMACEUTICAL INDUSTRY PHARMACEUTICALS PHARMACIES PHYSICIANS POLICY MAKERS POPULATION GROUPS PRICE CONTROLS PRICE INCREASE PRICE INCREASES PRICE INFLATION PROCUREMENT PUBLIC HEALTH RATIONAL DRUG USE RETAIL RETAIL PRICE RETAIL PRICES SALES SOCIAL SECTORS SOCIAL WELFARE SUPPLIERS TENDERING THERAPIES TUBERCULOSIS UNEMPLOYMENT WHOLESALE PRICES |
| author |
Marquez, Patricio Bonch-Osmolovskiy, Mikhail |
| author_facet |
Marquez, Patricio Bonch-Osmolovskiy, Mikhail |
| author_sort |
Marquez, Patricio |
| title |
Action Needed : Spiraling Drug Prices Empty Russian Pockets |
| title_short |
Action Needed : Spiraling Drug Prices Empty Russian Pockets |
| title_full |
Action Needed : Spiraling Drug Prices Empty Russian Pockets |
| title_fullStr |
Action Needed : Spiraling Drug Prices Empty Russian Pockets |
| title_full_unstemmed |
Action Needed : Spiraling Drug Prices Empty Russian Pockets |
| title_sort |
action needed : spiraling drug prices empty russian pockets |
| publisher |
World Bank, Washington, DC |
| publishDate |
2010-02 |
| url |
http://documents.worldbank.org/curated/en/2010/02/11900772/action-needed-spiraling-drug-prices-empty-russian-pockets https://hdl.handle.net/10986/10211 |
| work_keys_str_mv |
AT marquezpatricio actionneededspiralingdrugpricesemptyrussianpockets AT bonchosmolovskiymikhail actionneededspiralingdrugpricesemptyrussianpockets |
| _version_ |
1807154949385093120 |